Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose valsartan crossover study for sympathetic hyperactivity in chronic kidney disease and hypertension
NL-OMON31888Phase 3Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valsartan in hypertension (HTN) and chronic kidney disease (CKD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Effect of increasing valsartan dose on muscle sympathetic nerve activity. Planned start May 2008; status: withdrawn.
02
Drugs
valsartan
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON31888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31888.